Effect of Ketoconazole On Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

被引：1
|
作者：
Cotreau, M. [1 ]
Siebers, N.
Massmanian, L. [1 ]
Strahs, A. [1 ]
Vargo, D. [1 ]
机构：
[1] AVEO Oncol, Clin Pharmacol, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72392-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
595
引用
下载
收藏
页码：182 / 183
页数：2
相关论文
共 50 条
  • [31] PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)
    Hutson, T.
    Rathmell, W. K.
    Feng, B.
    Robinson, M. O.
    Gyuris, J.
    Lin, J.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2014, 25
  • [32] A Tyrosine Kinase Inhibitor-Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor
    Li, Feng
    Jiang, Sheng
    Zu, Youli
    Lee, Daniel Y.
    Li, Zheng
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (09) : 1525 - 1531
  • [33] Cloning, expression and characterization of human vascular endothelial growth factor receptor 1 tyrosine kinase
    Zhuang, SF
    Ye, QZ
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2002, 34 (01): : 39 - 44
  • [34] Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer
    Fiore, Michele
    D'Angelillo, Rolando Maria
    Greco, Carlo
    Fioroni, Iacopo
    Ippolito, Edy
    Santini, Daniele
    Ramella, Sara
    CHEMOTHERAPY, 2018, 63 (02) : 83 - 89
  • [35] Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence
    Cetin B.
    Bilgetekin I.
    Cengiz M.
    Ozet A.
    Drugs & Therapy Perspectives, 2017, 33 (8) : 395 - 402
  • [36] Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia, Pooja
    Morgan, Charity
    Choueiri, Toni K.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] IDENTIFICATION OF THE KDR TYROSINE KINASE AS A RECEPTOR FOR VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR
    TERMAN, BI
    DOUGHERVERMAZEN, M
    CARRION, ME
    DIMITROV, D
    ARMELLINO, DC
    GOSPODAROWICZ, D
    BOHLEN, P
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 187 (03) : 1579 - 1586
  • [38] Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition
    Fletcher, Anthony M.
    Bregman, Carla L.
    Woicke, Jochen
    Salcedo, Theodora W.
    Zidell, Robert H.
    Janke, Helen E.
    Fang, Hengsheng
    Janusz, William J.
    Schulze, Gene E.
    Mense, Mark G.
    TOXICOLOGIC PATHOLOGY, 2010, 38 (02) : 267 - 279
  • [39] KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth
    Nakamura, K
    Yamamoto, A
    Kamishohara, M
    Takahashi, K
    Taguchi, E
    Miura, T
    Kubo, K
    Shibuya, M
    Isoe, T
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (12) : 1639 - 1649
  • [40] Specific inhibitor of the epidermal growth factor receptor tyrosine kinase
    Fry, D.W.
    Kraker, A.J.
    McMichael, A.
    Ambroso, L.A.
    Nelson, J.M.
    Leopold, W.R.
    Connors, R.W.
    Bridges, A.J.
    Science, 1994, 265 (5175)
12345